著者

TOSHIYUKI HASEYAMA TOSHIKI FUJITA FUJIKO HIRASAWA MIKAKO TSUKADA HIDEKI WAKUI ATSUSHI KOMATSUDA HIROSHI OHTANI AKIRA B. MIURA HIROKAZU IMAI AKIO KOIZUMI

出版者

Tohoku University Medical Press

雑誌

The Tohoku Journal of Experimental Medicine (ISSN:00408727)

巻号頁・発行日

vol.198, no.4, pp.233-244, 2002 (Released:2004-04-19)

参考文献数

26

被引用文献数

32 43

---

The Akita mouse, which has a mutation (Cys96Tyr) in the insulin 2 gene (Ins2Akita), is a model for diabetes. The male Akita mouse has diabetes, while females develop mild diabetes. This study aimed to investigate renal complications in the Akita mouse model, which has been maintained in a heterozygous state Ins2Akita (+/−) with a C57BL/6 background (B6). Renal function (BUN, creatinine), serum IgA concentrations and histological changes in the kidneys were evaluated in diabetic and control mice in a B6 background. Five each of male and female mice per group (diabetes vs. control) were killed at 10, 20, 30 and 40 weeks of age. The influence of major histocompatibility antigens (MHC) on renal complications was tested using male diabetic mice in a C3H/He (C3H) background. When compared with controls, diabetic males, but not females, developed impaired renal function with elevation of serum IgA after 30 weeks of age. Diabetic glomerulosclerosis advanced with age in both sexes. Diffuse granular mesangial deposits of IgA were detected by immunofluorescence microscopy in diabetic males after 20 weeks. We tested whether the IgA-associated lesions were influenced by MHC using diabetic males in a C3H background. Similar degrees of diabetic glomerulosclerosis and glomerular IgA deposition were found in mice with C3H and B6 backgrounds. Akita mouse is a unique mouse model showing both mesangial sclerosis and IgA nephropathy.

著者

Masato Sawamura Atsushi Komatsuda Masaru Togashi Hideki Wakui Naoto Takahashi

出版者

一般社団法人 日本内科学会

雑誌

Internal Medicine (ISSN:09182918)

巻号頁・発行日

vol.56, no.6, pp.631-636, 2017-03-15 (Released:2017-03-17)

参考文献数

14

被引用文献数

26

---

Objective We performed a prospective study to determine the efficacy and safety of denosumab on bone metabolic indices and bone mineral density (BMD) in 29 patients receiving long-term glucocorticoids (GCs) who had clinical risk factors for fracture. Methods Among these patients, 16 had systemic lupus erythematosus (SLE), 6 RA, 4 other autoimmune diseases, and 3 renal diseases. All patients received donosumab 60 mg at baseline and 6 months. Serum N-terminal cross-linked telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) levels were measured as bone metabolic indices. BMD at the lumbar spine (LSBMD) and femoral neck (FNBMD) were measured using dual energy X-ray absorptiometry and expressed as a percentage of the young adult mean (%YAM). Results Denosumab therapy significantly reduced serum NTX and BAP levels from baseline after 12 months (from 19.2 to 13.9 nmol BCE/L; from 11.9 to 9.2 U/L, respectively). In 18 patients treated with bisphosphonates before the start of denosumab therapy, the improvements in the LSBMD and FNBMD values were 1.5%YAM/year and 1.1%YAM/year, respectively. The LSBMD and FNBMD values were both significantly higher 12 months after denosumab therapy (3.5%YAM/year and 3.0%YAM/year, respectively). The LSBMD gain was significantly higher after denosumab therapy than during bisphosphonate therapy. No fractures were observed in any patients during denosumab therapy. Conlusion Denosumab is effective and safe in preventing bone resorption and BMD loss in patients treated with long-term GCs for inflammatory diseases. This is the first study showing a significant increase in not only LSBMD but also FNBMD in GC-induced osteoporosis after denosumab therapy.

著者

Hideki WAKUI Ikuko TADA Yasunori KIMURA Kosaku YOSHIDA Yasuyuki ENDO Akira B MIURA

出版者

The Japanese Society of Internal Medicine

雑誌

Japanese Journal of Medicine (ISSN:00215120)

巻号頁・発行日

vol.28, no.6, pp.736-739, 1989 (Released:2006-03-27)

参考文献数

11

被引用文献数

1 2

---

We report an Rh(D)-negative man with myelodysplastic syndrome who produced six anti-erythrocyte alloantibodies (anti-D, -C, -E, -Dia, -Jka and -S) in succession. Three of these antibodies (anti-E, -Jka and -S) were not noted until delayed hemolytic transfusion reactions occurred. Treatment with cortico-steroids was effective in preventing both further formations of antibodies and other transfusion reactions. It was very difficult to find blood compatible with the patient, but repetitive blood transfusions were required for his progressive anemia and thrombocytopenia. Several problems concerning the transfusion of blood in such a case are discussed.